Purpose and rationale: To define the role of IL-17 as a mediator of structural bone lesions
in psoriasis patients and patients with PsA. Primary Objective is the improvement of the
PsAMRIS synovitis score baseline vs. week 24.
Drug tested is Secukinumab 300 mg administered weekly for 4 weeks, then 4 weekly s.c. with a
duration total of 24 weeks. Indication for this study is Psoriasis (Pso) and psoriatic
arthritis (PsA).